HG302 Clinical Trial Initiation and Study Design

HuidaGene Therapeutics' HG302 is an investigational, single-dose, in vivo gene editing therapy targeting the DMD gene exon 51 splice donor site in patients with Duchenne Muscular Dystrophy (DMD). It utilizes a single adeno-associated virus (AAV) vector to deliver a high-precision CRISPR-hfCas12Max nuclease and guide RNA to muscle cells, aiming to induce permanent exon 51 skipping. NCT06594094 MUSCLE is an open-label, dose-escalation Phase 1 clinical trial conducted at the Shanghai Children's Medical Center in China, enrolling six ambulatory boys aged 4-8 years. The trial commenced in November 2024, with the first patient dosed in December 2024. The study will evaluate safety, tolerability, dystrophin restoration, motor function, and quality of life over a 26-week period following a single intravenous administration, with the study completion target set for September 2026.

Technical Differentiation and Validation Challenges

Unlike gene replacement therapies that express synthetic micro-dystrophin, HG302 aims to directly edit the patient's endogenous DMD gene to restore the expression of a longer form of dystrophin. Approximately 14% of DMD patients are eligible for exon 51 skipping therapy, and Sarepta Therapeutics (SRPT) markets Exondys 51 (eteplirsen, DMD pre-mRNA), an antisense oligonucleotide therapy, within this molecular group. While Exondys 51 requires weekly intravenous administration, HG302 aims for single-dose administration and sustained efficacy, making editing efficiency and the durability of dystrophin expression key competitive factors. However, the hepatotoxicity and immune response associated with AAV vectors, as well as off-target editing, including in germ cells, are critical risks that need to be addressed in the initial clinical trials.

Standard of Care and Competitive Landscape

Currently, Sarepta's Elevidys (delandistrogene moxeparvovec-rokl, micro-dystrophin), Exondys 51, Vyondys 53 (golodirsen), Amondys 45 (casimersen), Nippon Shinyaku's Viltepso (viltolarsen), and Italfarmaco's Duvyzat (givinostat, HDAC inhibitor) are marketed in the United States. The FDA granted initial approval for Elevidys on June 22, 2023, and expanded its indication on June 20, 2024; however, following reports of acute severe liver failure, the FDA limited its use to ambulatory patients aged 4 years and older in 2025 and added a boxed warning. A next-generation direct competitor is Precision BioSciences (DTIL)'s PBGENE-DMD, which is being evaluated in the U.S. Phase 1/2a FUNCTION-DMD trial for exon 45-55 deletion. If HG302's low AAV dose strategy proves clinically effective, it could differentiate itself from existing high-dose gene therapies in terms of safety profile.

Regulatory and Market Implications

The FDA granted HG302 Orphan Drug Designation (ODD) for rare pediatric diseases (RPDD) on December 19, 2023, and ODD on January 23, 2024, providing development support and the potential for seven years of market exclusivity in the U.S. upon approval. These designations do not guarantee approval or efficacy; therefore, the safety, dystrophin expression levels in muscle biopsies, and changes in motor function observed in this trial will serve as the basis for subsequent development. The global DMD therapeutics market was estimated at approximately USD 3.35 billion in 2024, with North America accounting for approximately USD 1.34 billion, making it a commercially attractive area within rare diseases. For HuidaGene, which is not publicly listed, the initial human data will be a key inflection point in determining its partnership potential with global pharmaceutical companies and securing subsequent funding.